A Novel 90-kbp Deletion of RUNX2 Associated with Cleidocranial Dysplasia

Yanli Zhang and Xiaohong Duan *

Abstract: Cleidocranial dysplasia (CCD) is a rare autosomal dominant skeletal dysplasia caused by runt-related transcription factor 2 (RUNX2) mutations. In addition to the regular missense, small or large fragment deletions are the common mutation types of RUNX2. This study aimed to find the rules of deletions in RUNX2. The clinical information of one Chinese CCD family was collected. Genomic DNA was extracted for whole-exome sequencing (WES). Bioinformatics analyzed the pathogenicity of the variants. Polymerase chain reaction (PCR) and Sanger sequencing were carried out using specific primers. RT-PCR and Q-PCR were also used to detect the mRNA level of RUNX2. The CCD studies related with deletions in RUNX2 from 1999 to 2021 from HGMD and PubMed were collected and analyzed for the relationship between the phenotypes and the length of deleted fragments. The proband presented typical CCD features, including delayed closure of cranial sutures, clavicle dysplasia, abnormal teeth. WES, PCR with specific primers and Sanger sequencing revealed a novel heterozygous 90-kbp deletion in RUNX2 (NG_008020.2 g.103671~193943), which caused a substitution (p.Asn183Ile) and premature termination (p.Asp184*). In addition, the mRNA expression of RUNX2 was decreased by 75.5% in the proband. Herein, 31 types of deletions varying from 2 bp to 800 kbp or covering the whole gene of RUNX2 were compared and the significant phenotypic difference was not found among these deletions. The CCD phenotypes were related with the final effects of RUNX2 mutation instead of the length of deletion. WES has the defects in identifying large indels, and direct PCR with specific primers and Sanger sequencing could make up for the shortcoming.

Keywords: cleidocranial dysplasia; large fragment deletion; RUNX2; novel mutation

1. Introduction

Cleidocranial dysplasia (CCD; MIM 119600) is a rare hereditary disease. It exhibits delayed closing or non-closing of the fontanels, aplastic or hypoplastic clavicles, and multiple dental anomalies. The reported dental malformations of CCD include retained deciduous teeth or delayed eruption of permanent and supernumerary teeth [1,2]. The phenotypic spectrum of CCD may be varied. CCD exhibits autosomal dominant heredity with an approximate prevalence of 1:1,000,000 [3].

CCD has been ascribed to the mutations in the runt-related transcription factor 2 (RUNX2) gene, which plays a critical role in bone metabolism by regulating the differentiation between osteoblasts and osteoclasts [4]. RUNX2 protein contains a highly conserved Runt domain [5,6]. Reportedly, the common mutations in RUNX2 included chromosomal translocations and deletions, insertion, deletion, missense, nonsense, splice-site, and frameshift mutations [7]. To date, 200 heterozygous mutations in RUNX2 have been identified in individuals with CCD (Human Gene Mutation Database, HGMD, www.hgmd.cf.ac.uk, accessed on 29 April 2022) [6,8]. The majority of RUNX2 mutations were missense, primarily in the Runt domain [7]. Approximately 13% of the reported...
CCD cases have microdeletions in RUNX2 [9]. Whether the large deletion mutation has a more significant impact on the function of the RUNX2 gene compared to microdeletions and missense mutation is yet unknown. In order to elucidate the characteristics of a large deletion mutation in RUNX2 with CCD. Herein, we reported a Chinese CCD family with a novel 90-kbp deletion and summarized the reported deletions of the RUNX2 gene in HGMD and literature.

2. Materials and Methods

2.1. Clinical Manifestations

The proband was an 18-year-old male, referred to the Clinic of Oral Rare Diseases and Genetic Diseases, School of Stomatology at the Fourth Military Medical University, with the chief complaint of retention of deciduous teeth and abnormal facial features. The patient, his mother and his sister were examined and evaluated with panoramic radiographs or computed tomography (CT). This study was approved by the Ethics Committee of the School of Stomatology, The Fourth Military Medical University (approval no. 2018-014). Informed consent was obtained from all the participants in this study.

2.2. Whole-Exome Sequencing (WES) and Identification of Variants

Genomic DNA (gDNA) was extracted from peripheral blood samples of patients with CCD and his family members using QIAamp DNA Blood Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. WES containing exome capture, high-throughput sequencing, and common filtering was performed using Annoroad Gene Technology (Annoroad, Beijing, China). Alignment of the sequence reads, indexing of the reference genome, variant calling, and annotation were carried out using the Agilent SureSelect Human All Exon V6 system (Agilent Technologies, Santa Clara, CA, USA). Valid sequencing data of WES are mapped to the human reference genome GRCh37 using the Maq program.

Six pathogenicity prediction software (SIFT, PolyPhen-2 HVAR, PolyPhen-2 HDIV, MutationAssessor, MutationTaster, and CADD) [10] were used for mutation identification as likely damaging, deleterious, and disease causing; due to the possibility of amino acid alternation, the nonsense or frameshift (insertion or deletion) mutation was considered; the variants occurring in exon or splice sites and associated with CCD or involved in bone development were prioritized. All variants not relevant to known phenotypes or inheritance patterns were excluded; the variant was previously described as disease-causing in the HGMD or in the open published literature.

2.3. Polymerase Chain Reaction (PCR) and Sanger Sequencing

WES and bioinformatic analysis identified RUNX2 as a pathogenic gene of the family, then disease-associated RUNX2 mutation was further confirmed by PCR using two pairs of specific primers for RUNX2 (NM_001024630.4) (Pair 1: forward (F): 5'-GGCCATTACTGGACTTGGACT-3', reverse (R1): 5'-TCATCAAAGGAGCCATAATGCT-3'; Pair 2: forward (F): same as pair 1, reverse (R2): 5'-TAGGGCTAGTACTATAATGTAAC-3'). PCR was performed using 1 µg of template gDNA, 0.5 µL of each primer (10 µM), and 10 µL Taq PCR MasterMix (TaKaRa, Shiga, Japan) in a reaction volume of 20 µL. The amplification reactions were as follows 95 °C for 5 min, followed by 35 cycles of 95 °C for 1 min, 58 °C for 30 s, and 72 °C for 1 min, with a final extension of 72 °C for 7 min. The PCR products were visualized by 1% agarose gel electrophoresis and analyzed by Sanger sequencing on an ABI 3500 automated sequencer (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). Sequence data were analyzed using Sequencher software (version 5.0; Gene Codes Co., Ann Arbor, MI, USA).

2.4. Quantitative PCR Analysis (Q-PCR)

To validate the effect of the mutation, we performed Q-PCR and Reverse Transcription-polymerase chain reaction (RT-PCR) assays to determine the mRNA level of the RUNX2.
According to the manufacturer’s instructions, total RNA was extracted from 293 cells using Trizol™ reagent (Life Technologies, Carlsbad, CA, USA), or from whole blood samples of the proband and his family members using RNAprep pure Blood kit (Tiangen, Beijing, China). The concentration of the isolated RNA was determined by Thermo Scientific NanoDrop 2000/2000c spectrophotometer. cDNA was reverse transcribed using PrimeScript™ RT Master Mix (Takara, Dalian, China). The third pair of RUNX2 primers for Q-PCR or RT-PCR were as follows: forward (F3): 5′-TCATGGCGGGTAACGATGAA-3′, reverse (R3): 5′-TCCCGAGGTCCATCTACTGT-3′. Q-PCR was performed in a reaction volume of 20 µL containing 10 µL of SYBR Premix Ex Taq (TaKaRa), 100 ng cDNA, and 0.2 µL of each primer (10 µM). The reaction was as follows: 95 °C for 5 min and 40 cycles of 95 °C for 5 s, 62 °C for 15 s, and 72 °C for 15 s. The data were normalized to that of the control cDNA from 293 cells. The relative expression levels were calculated using the ΔΔCT method.

2.5. Predictions of the Protein Structure

The mutant RUNX2 protein was analyzed using the SWISS-MODEL software. The known structure of the Runt domain of RUNX1 protein was used as the template of RUNX2.

2.6. Retrospective Study

We summarized the reported deletions of the RUNX2 gene in HGMD and literature. The related CCD references were searched with respect to the large deletion in CCD patients. The following keywords were used to search the related references (1991 to present) from PubMed: cleidocranial dysplasia, deletion, and RUNX2. A total of 19 articles that matched the search criteria were retrieved from PubMed, and only those references describing the deletions of RUNX2 were included in our analysis. Finally, 31 deletions varying from 2 bp to 800 kbp or covering the whole gene of RUNX2 were included to summarize the general characteristics of deletion mutation in CCD with RUNX2 mutation.

3. Results

3.1. Clinical Findings

The proband (II2) was diagnosed with CCD. The patient showed typical CCD phenotypes: abnormal facial features, underdevelopment of the middle face, protrusion of mandible, and typical dental abnormalities of CCD such as retention of primary teeth (Figure 1). CT examination revealed remarkable open fontanelles, delayed closure of cranial sutures (Figure 1a), maxilla dysplasia, hypoplastic of clavicles, and multiple dental anomalies (Figure 1b). Panoramic radiograph showed retention of 14 deciduous teeth, failed eruption of 16 permanent teeth, and 13 supernumerary teeth (Figure 1c). No other signs of mental retardation or physical disability were observed in the patient. The mother (I2) and sister (II1) of the proband did not have any features associated with CCD.

3.2. Genetic Findings

After filtering and basic bioinformatic analysis of the WES raw data of the proband and his mother and sister, a heterozygous mutation in the RUNX2 gene was revealed. A speculated 68 bp insertion mutation (c.547_548ins) in exon 4 of RUNX2 (NM_001024630) was reported in the proband, which was not found in the non-affected members of the family.

3.3. PCR and Sanger Sequencing to Determine Mutation

The first pair of primers were designed around c.547 of RUNX2 (the forward (F) and reverse primer (R1) were in introns 3 and 4, respectively) (Figure 2a) and could result in 341 bp PCR products. Then the regular PCR was performed for the proband and his mother and sister. However, Sanger sequencing of PCR bands did not show any insertion or deletion in the proband (Figure 2d). Then we compared the sequence of the “inserted 68 bp” and found the 68 bp fragment was actually a part sequence of intron 7 of RUNX2. Thus, we assumed there might be a large deletion from exon 4 to intron 7. So we designed a new reverse primer (R2) in intron 7 (Figure 2a). Intriguingly, the proband had a positive
band (Figure 2c) while other non-affected members did not amplify successfully due to the long distance between two primers of F and R2. The new PCR products (F/R2) of the proband were subjected to Sanger sequencing, and the exact breakpoints of the deletion were identified compared to the reference sequence of RUNX2. The 90,273 bp deletion lay between exon 4 and intron 7 (NG_008020.2 g.103671~193943) (Figure 2d), which was detected in the proband but not in the non-affected family members or the 50 unrelated healthy Chinese volunteers. Furthermore, this mutation has not been reported previously.

3.2. Genetic Findings
After filtering and basic bioinformatic analysis of the WES raw data of the proband and his mother and sister, a heterozygous mutation in the RUNX2 gene was revealed. A speculated 68 bp insertion mutation (c.547_548ins) in exon 4 of RUNX2 (NM_001024630) was reported in the proband, which was not found in the non-affected members of the family.

3.3. PCR and Sanger Sequencing to Determine Mutation
The first pair of primers were designed around c.547 of RUNX2 (the forward (F) and reverse primer (R1) were in introns 3 and 4, respectively) (Figure 2a) and could result in 341 bp PCR products. Then the regular PCR was performed for the proband and his mother and sister. However, Sanger sequencing of PCR bands did not show any insertion or deletion in the proband (Figure 2d). Then we compared the sequence of the "inserted 68 bp" and found the 68 bp fragment was actually a part sequence of intron 7 of RUNX2. Thus, we assumed there might be a large deletion from exon 4 to intron 7. So we designed a new reverse primer (R2) in intron 7 (Figure 2a). Intriguingly, the proband had a positive band (Figure 2c) while other non-affected members did not amplify successfully due to the long distance between two primers of F and R2. The new PCR products (F/R2) of the proband were subjected to Sanger sequencing, and the exact breakpoints of the deletion were identified compared to the reference sequence of RUNX2. The 90,273 bp deletion lay between exon 4 and intron 7 (NG_008020.2 g.103671~193943) (Figure 2d), which was detected in the proband but not in the non-affected family members or the 50 unrelated healthy Chinese volunteers. Furthermore, this mutation has not been reported previously.

3.4. Bioinformatics Analysis
The human RUNX2 gene maps to chromosome 6p21 and consists of 8 exons encoding a 521-amino acid protein (NP_001019801.3). The novel deletion mutation causes a frameshift and subsequent premature translation termination. The Q184X truncating nonsense mutation generates a truncated 183-amino acid protein lacking a part of the Runt homologous domain (RHD), nuclear localization signal (NLS), and a part of the proline-serine/threonine rich region (PST). Additionally, we used SWISS-MODEL software to predict the effect of in-frame deletion on the overall protein structure. The three-dimensional (3D) structures of the wild-type and mutant RUNX2 proteins (g.103671~193943 del 90273) differed markedly. The novel deletion of 90-kbp in RUNX2 produced a substantially truncated protein shorter than the wild-type protein, and α-helix and β-sheet were reduced in number and length (Figure 2e).
detected in the proband but not in the non-affected family members or the 50 unrelated healthy Chinese volunteers. Furthermore, this mutation has not been reported previously.

Figure 2. PCR and Sanger sequencing to determine mutation. (a) Schematic map of the deleted fragment and designed primer in RUNX2 gene. Exons were labeled as solid rectangles in blue or red. The red zone between exon 4 and intron 7 represents a 90-kbp nucleotide detection. The first and second pairs of primers are F/R1 and F/R2, respectively. (b) Pedigree map. Arrow indicates the proband. The clinical phenotype and genotype of I1 is unknown and thus designated with question mark. (c) PCR result of RUNX2 analysis. A 302-bp PCR product of the proband using the second pair of primers (F/R2) was amplified in the proband, not in other family members of I2 and II1, in which a 90574-bp fragment was supposed to be amplified. (d) Comparing the sequencing chromatograms around g.103672A (c.547A) of RUNX2 of the proband. The upper one and lower one were from the PCR products amplified using the first pair of primers (F/R1), and the second pair of primers (F/R2), respectively. In the wild-type chain (upper), g.103673A (green) was next to g.103672A (green); while g.193944T (red) was followed by g.103672A (green) in the mutant chain (lower). (e) Predictive 3D structures of the wild-type and mutant RUNX2 proteins using SWISS-MODEL. Green ribbon represents the β-sheet, and the blue ribbon represents α-helix.

3.5. RUNX2 Expression Analysis

To further investigate the effect of the mutation, Q-PCR and regular RT-PCR were performed to determine the expression levels of RUNX2. The upstream and downstream primers were designed in exons 4 and 5, respectively. Q-PCR results indicated that the RUNX2 levels were significantly down regulated in the proband compared to normal controls. The proband exhibited a 75.5% decrease in wild-type RUNX2 levels resulting in CCD; and his mother and sister had the slight up (14.5%) and down (34.3%) changes.
WES has some defects in identifying large indels or other structural variations. PCR with

**RUNX2** function than the small deletions or missense mutations. Therefore, when the large

mutation, we collected the reported deletions, large deletions, and translocation

**RUNX2** assessed

primers were designed in exons 4 and 5, respectively. Q-PCR results indicated that the

proband did not have an obvious band (Figure 3b).

Comparing to the control (Figure 3a). RT-PCR analysis showed the similar results and the proband did not have an obvious band (Figure 3b).

3.4. Bioinformatics Analysis

The human **RUNX2** gene maps to chromosome 6, and consists of 8 exons encoding

the final amino acid changes, which in turn determine the related CCD phenotypes.

4. Discussion

About 60–70% of the reported CCD cases with a clinical diagnosis harbor mutations in **RUNX2**. Currently, no other causative gene is indicated in CCD cases [11–13]. Hitherto, at least 200 **RUNX2** mutations have been reported in CCD patients [12,14]. The mutation types of **RUNX2** include missense, nonsense, frameshift, splicing, insertion, microdeletions, and microduplication (HGMD).

The microdeletions may be found in up to 10%–13% of the cases with CCD in **RUNX2** [15]. Approximately 2/19 (10%) of CCD cases may be caused by large chromosomal rearrangements that affect the **RUNX2** gene [16]. In this study, we identified a novel 90-kbp deletion (g.103671–193943 del 90273) between exon 4 and intron 7 in **RUNX2** in a Chinese CCD patient. In order to characterize the large deletion mutation in CCD with **RUNX2** mutation, we collected the reported deletions, large deletions, and translocation breakpoints, and summarized them in Table 1.

The variation in the deleting length of in **RUNX2** have not been compared previously. Fluorescence in situ hybridization (FISH) analysis, Q-PCR, or comparative genomic hybridization (CGH) microarray have been employed to identify these deletions, while PCR and Sanger sequencing were seldom used to elucidate the details of the deletion. In the current study, the WES reports from the company suggested a 68 bp insertion in **RUNX2** between c.547 and c.548, which could not be proved by us. On the contrary, we revealed that the “68 bp inserting fragment” was actually localized in intron 7 of **RUNX2** and finally identified a large deletion in the gene using a specific pair of primers and PCR. Therefore, WES has some defects in identifying large indels or other structural variations. PCR with specific primers and Sanger sequencing could help in elucidating the details of the deletion gap. Moreover, RT-PCR or Q-PCR are convenient and cost-effective supplementary tools to identify the indel effects on the mRNA expression.

Based on the retrospective analysis of large deletion of **RUNX2** with the described mutations details, we found that most of them result in a frameshift and premature translation termination, which had the same effects with point mutations causing premature translation termination. The large deletion mutation does not mean a more severe impact on the **RUNX2** function than the small deletions or missense mutations. Therefore, when the large fragment or even the entire gene of **RUNX2** is deleted, their pathogenic effects depend on the final amino acid changes, which in turn determine the related CCD phenotypes.
Table 1. Gross deletions in RUNX2 gene.

| Number | Description | Predicted Changes in Protein or RNA | Methods | Location | Reference |
|--------|-------------|-------------------------------------|---------|----------|-----------|
| 1      | ~7.3 Mb incl entire gene + VEGFA + NFKBIE | Microarray | entire areas | QA | [12] |
| 2      | ~70 kbp incl entire gene | aCGH | entire areas | QA | [17] |
| 3      | 11.87 kbp incl ex. 8–9 | Microarray | PST | QA | [18] |
| 4      | nt.220 del173 | Sanger sequencing | PST | QA | [19] |
| 5      | 2.1 Mb, entire gene + 20 additional genes | Q-PCR, aCGH | entire areas | QA | [15] |
| 6      | nt.950-971del22 | Sanger sequencing | PST | QA | [20] |
| 7      | 500 kbp incl ex. 1–5 | Q-PCR, FISH | QA + RHD + NLS | QA | [16] |
| 8      | 750 kbp incl ex. 1–5 | Q-PCR, FISH | QA + RHD | QA | [16] |
| 9      | c.227_306del80 | p.Leu317ThrfsX483 | Sanger sequencing | QA | [21] |
| 10     | 9.7 Mb incl. entire gene + CUL7, VEGFA and NFKBIE | aCGH | entire areas | QA | [22] |
| 11     | c.230_276del47 | p.Ala76GlyfsX58 | Sanger sequencing | QA | [15] |
| 12     | c.718_721del47 | p.Ser240CysfsX9 | Sanger sequencing | QA | [15] |
| 13     | c.879_885del7 | p.Ser294ArgfsX12 | Sanger sequencing | QA | [15] |
| 14     | entire gene | Q-PCR, aCGH | entire areas | QA | [15] |
| 15     | ex. 1–3 | MLPA | QA + RHD | QA | [23] |
| 16     | ex. 2 | MLPA | RHD | QA | [24] |
| 17     | 125.6 kbp incl ex. 2–6 | Sanger sequencing | QA + RHD + NLS | QA | [9] |
| 18     | ex. 2–8 | Q-PCR | QA + RHD | QA | [15] |
| 19     | ex. 3 | Q-PCR | RHD | QA | [15,25] |
| 20     | ex. 3–6 | Q-PCR | RHD + NLS + PST | QA | [15] |
| 21     | ex. 6–8 | Q-PCR | PST | QA | [15] |
| 22     | ex. 7 | Q-PCR | PST | QA | [15] |
| 23     | ex. 7–8 | Q-PCR | PST | QA | [15] |
| 24     | c.241_258del18 | p.84_89del | Sanger sequencing, MLPA | QA | [26,27] |
| 25     | c.243-260del18 | P.85_90 del | Sanger sequencing | QA | [27,28] |
| 26     | ~500 kbp incl ex. 1–4 + SUPT3H | CNV analysis by microarrays | QA + RHD + NLS | QA | [29] |
| 27     | c.443_454del12insG | p.Val148GlyfsX9 | sequencing | RHD | [30] |
| 28     | ex. 2–9 | unmentioned | QA + RHD + NLS | QA | [30] |
| 29     | ex. 6–9 | unmentioned | QA + RHD + NLS | QA | [30] |
| 30     | ~800 kbp incl entire gene | aCGH | entire areas | QA | [31] |
| 31     | ~90 kbp incl ex. 4–7 | p.Asn294LysfsX1 | Sanger sequencing | RHD + NLS | This paper |

incl: include; del: deletion mutation; ins: insertion mutation; ex: exon; fs: frameshift; aCGH: array comparative genomic hybridization; FISH: fluorescence in situ hybridization analysis; MLPA: multiplex ligation-dependent probe amplification; WES: whole exome sequencing; CNV: subsequent copy number variation; QA: glutamine–alanine repeats domain; RHD: Runt homologous domain; NLS: nuclear localization signal; PST: proline/serine/threonine rich region.

Type I RUNX2 (MRIPV isoform; UniProt: Q13950-2) [32] and type II RUNX2 (MASNS isoform; UniProt: Q13950-1) [33] are two isoforms with different spatiotemporal patterns. The promoter of type II RUNX2 is termed “bone-related” because it drives the expression of the isoform widely in bones. The reference sequence of type II RUNX2 mRNA (NM_001024630; NP_001019801.3) was used in the retrospective analysis of deletions. RUNX2 is a multidomain protein containing glutamine–alanine repeats domain (QA), Runt homologous domain (RHD), nuclear localization signal (NLS), and the proline/serine/threonine rich region (PST) [30]. Most missense mutations of RUNX2 uniquely occurred within the RHD region [30]. The missense mutations may prevent RUNX2 binding to DNA, while the nonsense mutations may effectuate the biosynthesis of the truncated protein. The frameshift mutations are detected throughout the gene. The current retrospective study found that deletion mutations occurred throughout the RUNX2 gene: 16.1% in
the QA domain, 9.7% in the RHD region, 22.6% in the PST region, and 51.6% covered more than one domain.

The functional expressing level of RUNX2 is required for the formation of bone. The threshold of normal RUNX2 level to keep the normal bone development or causing CCD phenotypes was not clear. 79% of Runx2-deficient mice did not show the skeletal abnormalities due to harboring the partial wild-type Runx2 transcripts [34]. Lou et al. reported that wild-type Runx2 levels decreased to 70%, resulting in the CCD phenotype [34]. Another study reported that when the RUNX2 activity declines to about 50%, the growth of the skeleton deteriorates and gradually worsens with further loss of gene activity in Japanese patients [5]. A mild CCD was reported as mosaicism with the deletion of exons 3–6 of RUNX2, who carried about 15% mosaic DNA [15]. In another study, the mother of one CCD patient did not exhibit any CCD phenotypes but carried about 21.8% mosaic DNA microdeletion in exons 1–4 of the RUNX2 gene [29]. The current study found that the mRNA level of RUNX2 in the proband (II2) was decreased by 75.5%, and significant CCD symptoms occurred. We also found that the mRNA level of RUNX2 was reduced by 34.3% in the proband’s sister (II1) who did not have the RUNX2 mutation and CCD symptoms. Therefore, it could be deduced that other factors may regulate RUNX2 expression levels, but not sufficiently to cause the CCD-like phenotypic features.

Dentists are often the first clinicians to meet the CCD patients due to dental anomalies, including retention of deciduous teeth, failed eruption of permanent teeth, and supernumerary teeth. We recommended that the dentists familiarize themselves with the phenotypes of CCD and recognize it as a genetic disease.

In summary, we identified a novel 90-kbp deletion (g.103671–193943 del 90273) in the RUNX2 gene in a Chinese family with CCD and suggested a PCR related detecting method for the large missing fragments. We also summarized the characteristics of all the reported deletions in RUNX2 and found that the CCD phenotypes were related to the final effects of mutation on protein instead of the length of deletion.

Author Contributions: X.D. designed and supervised the experiments and wrote the article. Y.Z. performed the experiments, analyzed the data, and wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the National Nature Science Foundation of China, Grant/Award Number: 81974145, 82100958. Key R&D plan of Shaanxi Province (2021 ZDLSF02-13). Natural Science Foundation of Shanxi Province (2021JM-236) and National clinical research center for oral diseases Key Project LCA202013.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the School of Stomatology, The Fourth Military Medical University (protocol code 2018-014 and date of approval 24 February 2018).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement: Research data not shared.

Acknowledgments: We are grateful to the proband and his families for their participated in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Zhang, X.; Liu, Y.; Wang, X.; Sun, X.; Zhang, C.; Zheng, S. Analysis of novel RUNX2 mutations in Chinese patients with cleidocranial dysplasia. *PloS ONE* 2017, 12, e181653. [CrossRef] [PubMed]
2. Quack, I.; Vonderstrass, B.; Stock, M.; Aylsworth, A.S.; Becker, A.; Brueton, L.; Lee, P.J.; Majewski, F.; Mulliken, J.B.; Suri, M.; et al. Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. *Am. J. Hum. Genet.* 1999, 65, 1268–1278. [CrossRef] [PubMed]
3. Hsueh, S.J.; Lee, N.C.; Yang, S.H.; Lin, H.I.; Lin, C.H. A limb-girdle myopathy phenotype of RUNX2 mutation in a patient with cleidocranial dysplasia: A case study and literature review. *BMC Neurol.* 2017, 17, 2. [CrossRef] [PubMed]
4. Cardoso, B.M.; Dupont, J.; Castanhinha, S.; Ejarque-Albuquerque, M.; Pereira, S.; Miltenberger-Miltenyi, G.; Oliveira, G. Cleidocranial dysplasia with severe parietal bone dysplasia: A new (p.Val124Serfs) RUNX2 mutation. *Clin. Dysmorphol.* **2010**, *19*, 150–152. [CrossRef] [PubMed]

5. Yoshiida, T.; Kanegane, H.; Osato, M.; Yanagida, M.; Miyawaki, T.; Ito, Y.; Shigesada, K. Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. *Am. J. Hum. Genet.* **2002**, *71*, 724–738. [CrossRef]

6. Gao, X.; Li, K.; Fan, Y.; Sun, Y.; Luo, X.; Wang, L.; Liu, H.; Gong, Z.; Wang, J.; Wang, Y.; et al. Identification of RUNX2 variants associated with cleidocranial dysplasia. *Hereditas* **2019**, *156*, 31. [CrossRef]

7. Ma, D.; Wang, X.; Guo, J.; Zhang, J.; Cai, T. Identification of a novel mutation of RUNX2 in a family with supernumerary teeth and craniofacial dysplasia by whole-exome sequencing: A case report and literature review. *Medicine* **2018**, *97*, e11328. [CrossRef]

8. Gong, L.; Odilov, B.; Han, F.; Liu, F.; Sun, Y.; Zhang, N.; Zuo, X.; Yang, J.; Wang, S.; Hou, X.; et al. Identification a novel de novo RUNX2 frameshift mutation associated with cleidocranial dysplasia. *Genes Genomics* **2022**, *44*, 683–690. [CrossRef]

9. Lee, M.T.; Tsai, A.C.; Chou, C.H.; Sun, F.M.; Huang, L.C.; Yen, P.; Lin, C.C.; Liu, C.Y.; Wu, J.Y.; Chen, Y.T.; et al. Intragenic microdeletion of RUNX2 is a novel mechanism for cleidocranial dysplasia. *Genom. Med.* **2008**, *2*, 45–49. [CrossRef]

10. Duan, X.; Yang, S.; Zhang, H.; Wu, J.; Zhang, Y.; Ji, D.; Tie, L.; Boerkoel, C.F. A Novel AMELX Mutation, Its Phenotypic Features, and Skewed X Inactivation. *J. Dent. Res.* **2019**, *98*, 870–878. [CrossRef]

11. Farrow, E.; Nicot, R.; Wiss, A.; Laborde, A.; Ferri, J. Cleidocranial Dysplasia: A Review of Clinical, Radiological, Genetic Implications and a Guidelines Proposal. *Craniofac. Surg.* **2018**, *29*, 382–389. [CrossRef]

12. Puvabanditsin, S.; February, M.; Mayne, J.; Mcconnell, J.; Mehta, R. Cleidocranial Dysplasia with 6p21.1-p12.3 Microdeletion: A Case Report and Literature Review. *Cleft Palate-Craniofacial J.* **2018**, *55*, 891–894. [CrossRef]

13. Xin, Y.; Liu, Y.; Liu, D.; Li, J.; Zhang, C.; Wang, Y.; Zheng, S. New Function of RUNX2 in Regulating Osteoclast Differentiation via the AKT/NFATc1/CTSK Axis. *Calcif. Tissue Int.* **2020**, *106*, 553–566. [CrossRef]

14. Zhang, T.; Wu, J.; Zhao, X.; Hou, F.; Ma, T.; Wang, H.; Zhang, X.; Zhang, X. Whole-exome sequencing identification of a novel splicing mutation of RUNX2 in a Chinese family with cleidocranial dysplasia. *Arch. Oral Biol.* **2019**, *100*, 49–56. [CrossRef]

15. Ott, C.E.; Leschik, G.; Trotier, F.; Brunner, H.G.; Brussel, W.; Guillen-Navarro, E.; Haase, C.; Kohlhase, J.; Kotzot, D.; et al. Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasia. *Hum. Mutat.* **2010**, *31*, E1587–E1593. [CrossRef]

16. Hansen, L.; Riis, A.K.; Silahtaroglu, A.; Hove, H.; Lauridsen, E.; Eiberg, H.; Kreiborg, S. RUNX2 analysis of Danish cleidocranial dysplasia families. *Clin. Genet.* **2011**, *79*, 254–263. [CrossRef]

17. El-Gharbawy, A.H.; Peeden, J.J.; Lachman, R.S.; Graham, J.J.; Moore, S.R.; Rimoin, D.L. Severe cleidocranial dysplasia and hypophosphatasia in a child with microdeletion of the C-terminal region of RUNX2. *Am. J. Med. Genet. A* **2010**, *151*, 169–174. [CrossRef]

18. Takenouchi, T.; Sato, W.; Torii, C.; Kosaki, K. Progressive cognitive decline in an adult patient with cleidocranial dysplasia. *Eur. J. Med. Genet.* **2014**, *57*, 319–321. [CrossRef]

19. Zhou, G.; Chen, Y.; Zhou, L.; Thirunavukkarasu, K.; Hecht, J.; Chitayat, D.; Gelb, B.D.; Pirinen, S.; Berry, S.A.; Greenberg, C.R.; et al. CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. *Hum. Mutat.* **1999**, *8*, 2311–2316. [CrossRef]

20. Cunningham, M.L.; Seto, M.L.; Hing, A.V.; Bull, M.J.; Hopkin, R.J.; Leppig, K.A. Cleidocranial dysplasia with severe parietal bone dysplasia: C-terminal RUNX2 mutations. *Birth Defects Res. Part A Clin. Mol. Teratol.* **2006**, *76*, 78–85. [CrossRef]

21. Qi, Z.; Yang, W.; Meng, Y.; Liu, Y. Identification of three novel frameshift mutations in the RUNX2 gene in three sporadic Chinese cases with cleidocranial dysplasia. *Clin. J. Med. Genet.* **2014**, *31*, 415–419. [CrossRef]

22. Chen, C.P.; Lin, S.P.; Liu, Y.P.; Chern, S.R.; Wu, P.S.; Chen, Y.T.; Su, J.W.; Lee, C.C.; Wang, W. 6p21.2-p12.3 deletion detected by aCGH in an 8-year-old girl with cleidocranial dysplasia and developmental delay. *Gene* **2013**, *523*, 99–102. [CrossRef]

23. Franceschi, R.; Maines, E.; Fedrizzi, M.; Piemontese, M.R.; De Bonis, P.; Agarwal, N.; Bellizzi, M.; Di Palma, A. Familial cleidocranial dysplasia misdiagnosed as rickets over three generations. *Pediatr. Int.* **2015**, *57*, 1003–1006. [CrossRef]

24. Bedeschi, M.F.; Bonarrigo, F.; Manzoni, F.; Milani, D.; Piemontese, M.R.; Guez, S.; Esposito, S. Ehlers-Danlos syndrome versus cleidocranial dysplasia. *Ital. J. Pediatr.* **2014**, *40*, 49. [CrossRef]

25. Chen, M.; Lin, S.M.; Li, N.; Li, Y.; Li, Y.; Zhang, L. An induced pluripotent stem cell line (GZHMCI003-A) derived from a fetus with exon 3 heterozygous deletion in RUNX2 gene causing cleidocranial dysplasia. *Stem Cell Res.* **2021**, *51*, 102166. [CrossRef]

26. Dincsoy, B.F.; Dinckan, N.; Guven, Y.; Bas, F.; Altunoglu, U.; Kuvvetli, S.S.; Poyrazoglu, S.; Toksog, G.; Kayserili, H.; Uygur, Z.O. Cleidocranial dysplasia: Clinical, endocrinologic and molecular findings in 15 patients from 11 families. *Eur. J. Med. Genet.* **2017**, *60*, 163–168. [CrossRef]

27. Hashmi, J.A.; Almatrafi, A.; Latif, M.; Nasir, A.; Basit, S. An 18 bps in-frame deletion mutation in RUNX2 gene is a population polymorphism rather than a pathogenic variant. *Eur. J. Med. Genet.* **2019**, *62*, 124–128. [CrossRef]

28. Zeng, L.; Wei, J.; Zhao, N.; Sun, S.; Wang, Y.; Feng, H. A novel 18-bp in-frame deletion mutation in RUNX2 causes cleidocranial dysplasia. *Arch. Oral Biol.* **2018**, *96*, 243–248. [CrossRef]

29. Qian, Y.; Zhang, Y.; Wei, B.; Zhang, M.; Yang, J.; Leng, C.; Ge, Z.; Xu, X.; Sun, M. A novel Alu-mediated microdeletion in the RUNX2 gene in a Chinese patient with cleidocranial dysplasia. *J. Genet.* **2018**, *97*, 137–143. [CrossRef]
30. Berkay, E.G.; Elkanova, L.; Kalayci, T.; Uludag, A.D.; Altunoglu, U.; Cefle, K.; Mihci, E.; Nur, B.; Tasdelen, E.; Bayramoglu, Z.; et al. Skeletal and molecular findings in 51 Cleidocranial dysplasia patients from Turkey. *Am. J. Med. Genet. A* 2021, 185, 2488–2495. [CrossRef]

31. Wu, D.; Li, T.; Hou, Q.; Huo, X.; Wang, X.; Wang, T.; Yang, Y.; Liu, H.; Liao, S. Genetic analysis of a child with cleidocranial dysplasia and 6q21-q22.31 microdeletion. *Chin. J. Med. Genet.* 2018, 35, 253–256. [CrossRef]

32. Ogawa, E.; Maruyama, M.; Kagoshima, H.; Inuzuka, M.; Lu, J.; Satake, M.; Shigesada, K.; Ito, Y. PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosophila runt gene and the human AML1 gene. *Proc. Natl. Acad. Sci. USA* 1993, 90, 6859–6863. [CrossRef] [PubMed]

33. Mundlos, S.; Otto, F.; Mundlos, C.; Mulliken, J.B.; Aylsworth, A.S.; Albright, S.; Lindhout, D.; Cole, W.G.; Herrn, W.; Knoll, J.H.; et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell* 1997, 89, 773–779. [CrossRef]

34. Lou, Y.; Javed, A.; Hussain, S.; Colby, J.; Frederick, D.; Pratap, J.; Xie, R.; Gaur, T.; van Wijnen, A.J.; Jones, S.N.; et al. A Runx2 threshold for the cleidocranial dysplasia phenotype. *Hum. Mol. Genet.* 2009, 18, 556–568. [CrossRef]